An interventional study of Multimodal prehabilitation and standard of care in Primary Biliary Cholangitis (PBC), sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Liver Cirrhosis, Biliary with a site in Spain — 7 open to participants now, 12 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Spain.
Among the 32 studies in Liver Cirrhosis, Biliary with a site in Spain, this one is the 20th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2025, is the only one with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 29th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →7 of the 32 studies in Liver Cirrhosis, Biliary with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitario La Paz · Sites in Spain
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in Spain, Austria, Belgium and 4 more countries
Ages 18–70
Gilead Sciences · Sites in Spain, United States, Argentina and 26 more countries
Ages 18+
Ipsen · Sites in Spain, United States, Argentina and 25 more countries
Ages 18+
Hospital Mutua de Terrassa · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 11 · Phase 4 2
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is close to the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 129 across the 26 interventional studies, 1,750 across the 6 observational. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 32 have an industry lead sponsor. The 10 most frequent:
Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 54 are open to participants now.
Hospital Clinic of Barcelona has 1 study filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
2 of the studies in Liver Cirrhosis, Biliary with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07821463Fundacio Privada Mon Clinic BarcelonaEpidemiology of PrImary Biliary Cholangitis in Spain | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Liver Cirrhosis, Biliary with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The implementation of a non-pharmacological multimodal intervention program-including physical exercise, nutritional counseling, and psychological support-is expected to improve fatigue in patients with primary biliary cholangitis. Consequently, this improvement is anticipated to enhance quality of life and cognitive symptoms, while also positively impacting emotional, social, and occupational aspects.
From a pathophysiological perspective, it is hypothesized that chronic cholestasis and/or immune system activation, with the release of pro-inflammatory cytokines, leads to both central and peripheral alterations causing fatigue.
At the central level, systemic inflammation may induce neuronal senescence in the basal ganglia, resulting in altered functional connectivity networks dependent on these regions and/or structural and connectivity changes in areas involved in interoception, such as the insula and anterior cingulate cortex.
At the peripheral level, the hypothesis is that chronic inflammation mediated by anti-mitochondrial antibodies causes mitochondrial metabolic dysfunction in muscle cells, which would be reflected in changes observed in the gene expression analysis of these cells.
Improvement in fatigue following the multimodal intervention program is expected to be associated with normalization of the immunological profile, enhanced functional brain connectivity, and improved mitochondrial metabolism in muscle.
Primary biliary cholangitis (PBC) is a rare autoimmune disease that damages the small bile ducts and primarily affects women. Although it is a liver disease, its most common symptom is fatigue, affecting up to 60% of patients. Fatigue is a debilitating symptom, described by patients as "a brain fog" that causes concentration problems and memory loss, along with "a lack of energy" that leads to poor exercise tolerance and early exhaustion. This significantly impacts quality of life, negatively affecting family, social, and work-related activities. To the frustration of both patients and healthcare providers, fatigue is not correlated with the severity of liver disease, and there is currently no effective treatment.
Ursodeoxycholic acid (UDCA), the first-line treatment for PBC, has been shown to improve disease survival, but it does not appear to have an effect on fatigue, as demonstrated by a meta-analysis. Other treatments, such as bezafibrate, have also failed to show improvement in fatigue. Several clinical trials have tested treatments targeting different pathophysiological mechanisms, including selective serotonin reuptake inhibitors (SSRIs), stimulants like modafinil, and immunomodulatory therapies such as rituximab, all with negative results.
Currently, new drugs have been approved as second-line treatments for PBC, such as elafibranor and seladelpar. The latter may have some impact on fatigue; however, this was not the primary objective of the study, and the mechanisms associated with this improvement remain unclear.
One of the main reasons why no treatment exists is the lack of understanding of the underlying mechanisms. Fatigue is a complex and likely multifactorial symptom. It has been hypothesized that chronic immune system activation, leading to excessive production of inflammatory substances, could be a trigger. Additionally, it remains unknown whether alterations in bile acid composition, which are molecules with potent biological effects on multiple organs, could worsen fatigue. Furthermore, this chronic inflammation may induce changes in both the brain and muscles, contributing to the development of fatigue.
It has been demonstrated that physical exercise reduces systemic inflammation by lowering inflammatory substances and can also improve abnormalities in muscle energy production. Studies conducted in patients with other diseases associated with fatigue, such as multiple sclerosis, have shown that exercise programs can be beneficial for fatigue management.
At present, experience with physical training programs for PBC patients with fatigue is very limited. The results of a study conducted in the United Kingdom and another in Canada suggest that a home-based exercise program may improve fatigue. However, both studies have certain limitations, as the follow-up was remote, there was no supervision to ensure proper execution of the exercises or that they were performed at the prescribed intensity. Additionally, the effective exercise duration was only about 15 minutes, which, along with its moderate intensity, is unlikely to induce specific adaptations in mitochondrial biogenesis and efficiency. On the other hand, while patients with liver diseases generally express positive attitudes toward the benefits of supervised exercise, they also acknowledge a lack of confidence in initiating it independently.
Based on this evidence, an integrated exercise program is proposed, consisting of two phases: an initial supervised phase lasting eight weeks and a subsequent remote phase, combined with nutritional counseling and psychological support. It is hypothesized that this program will improve fatigue and consequently enhance quality of life, as well as alleviate associated cognitive symptoms (such as depression and sleep disturbances).
To better understand the changes occurring in the organs involved in fatigue, the investigators aim to analyze immune responses and bile acids to determine their potential association with fatigue, as has been observed in other autoimmune diseases. Additionally, potential alterations at both the brain and muscle levels will be explored.
At the neurological level, functional connectivity alterations in brain regions involved in fatigue will be studied using functional magnetic resonance imaging (fMRI). At the muscular level, changes in muscle metabolism will be analyzed by studying gene expression in muscle fibers. Muscle samples will be obtained using a minimally invasive technique called muscle microbiopsy, which involves a fine-needle puncture of a muscle and is not associated with complications. These studies will be conducted before and after the exercise program, aiming to observe the positive changes expected at all levels.
These studies will be conducted before and after the training program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For the study of the pathophysiology of fatigue, additional exclusion criteria will be established: Severe depression or neuropsychiatric disease, 2) Treatment with centrally acting drugs, 3) Muscular or systemic disease with potential muscle involvement, 4) treatment, 5) Sleep disorder, 6) Obesity (BMI >30).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 weeks program of tailored physical exercise program with nutritional and psychological counselling to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile.
Other: Multimodal prehabilitation
Standard Counselling: Patients in the control group will follow standard of care of the hospital and will be given general recommendations on physical activity, nutrition and stress/anxiety management.
Other: standard of care
The multimodal prehabilitation program will consist of: 1. twice-weekly supervised exercise training at the hospital gym for approximately 8 weeks (induction phase), followed by 16 weeks of telematic, supervised, home-based exercise (maintenance phase); 2. nutritional consultation, including diet optimization and supplementation if needed; 3. individual or group-based psychological support.
Participants in the control group will follow the standard of care provided by the hospital and will receive general recommendations on physical activity, nutrition, and stress/anxiety management.
Change in Fatigue Severity Assessed by PBC-40
To evaluate the effect of a non-pharmacological multimodal intervention program on fatigue severity and its impact in participants with primary biliary cholangitis (PBC). Fatigue will be assessed using the Primary Biliary Cholangitis-40 (PBC-40) fatigue domain, which consists of 11 items scored from 1 to 5. Scoring Range: 11 to 55; higher scores indicate greater fatigue.
Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).
Change in Fatigue Severity Assessed by Visual Analogue Scale
To evaluate the effect of a non-pharmacological multimodal intervention program on fatigue severity and its impact in participants with primary biliary cholangitis (PBC). Fatigue will be assessed using the Visual Analogue Scale (VAS) for fatigue, which captures the participant's perception of fatigue severity. Scoring Range: 0 (no fatigue) to 10 (worst imaginable fatigue).
Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).
Change in Fatigue Impact Assessed by Fatigue Impact Scale (FIS)
To evaluate the effect of a non-pharmacological multimodal intervention program on fatigue severity and its impact in participants with primary biliary cholangitis (PBC). Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS), which assesses the impact of fatigue on physical, cognitive, and psychosocial functioning. Scoring Range: 0 to 84; higher scores indicate greater fatigue-related impairment
Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).
Change in Cognitive Symptoms Assessed by PBC-40
To evaluate changes in cognitive symptoms using the Primary Biliary Cholangitis-40 (PBC-40) questionnaire. The cognitive domain ranges from 6 to 30 points. Higher scores indicate worse symptoms.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Extrahepatic Symptoms Assessed by PBC-40
To evaluate changes in extrahepatic symptoms using the Primary Biliary Cholangitis-40 (PBC-40) questionnaire. The symptoms domain ranges from 7 to 35 points. Higher scores indicate worse symptoms.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Quality of Life Assessed by EQ-5D-5L Index Score
To assess health-related quality of life using only the EQ-5D-5L index score derived from five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The index score ranges from -0.594 to 1, where higher scores indicate better health status.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Self-Perceived Health Status Assessed by EQ Visual Analogue Scale
To evaluate self-perceived overall health using the EQ Visual Analogue Scale (EQ-VAS), part of the EQ-5D-5L instrument, reported separately. The EQ-VAS ranges from 0 to 100, where 0 = worst imaginable health and 100 = best imaginable health.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Disability Assessed by the WHO Disability Assessment Schedule (WHODAS 2.0)
To measure disability and functional impairment. Scoring Range: 0 to 100; higher scores indicate greater disability.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Anxiety and Depression Assessed by the Hospital Anxiety and Depression Scale (HADS)
To evaluate levels of anxiety and depression. Scoring Range: 0 to 21 for each subscale (anxiety and depression); higher scores indicate greater symptom severity.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Sleep Quality Assessed by the Epworth Sleepiness Scale (ESS)
To assess daytime sleepiness as a proxy for sleep quality. Scoring Range: 0 to 24; higher scores indicate greater daytime sleepiness.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Work Productivity and Activity Impairment Assessed by the WPAI Questionnaire
To measure absenteeism and work productivity impairment. Percentage scores for absenteeism, presenteeism, overall work impairment, and activity impairment; higher percentages indicate greater impairment.
Time frame: Baseline, week 8 and/or after the exercise phase, and end of trial.
Change in Systemic Inflammation Assessed by Pro-Inflammatory Cytokines
To evaluate systemic inflammation and bile acid metabolism by analyzing a panel of pro-inflammatory cytokines (measured via ELISA), lysophosphatidic acid, autotaxin, and bile acids. Each biomarker will be quantified by the laboratory using standardized assays. Units of Measure: Concentrations reported in appropriate laboratory units (e.g., pg/mL, nmol/L) depending on the biomarker.
Time frame: Baseline and end of induction phase (2 months) for participants with fatigue; single time point for control groups.
Functional Connectivity Alterations in Brain Regions Assessed by fMRI.
To examine changes in functional connectivity in gray matter regions, including the basal ganglia and insula, using functional magnetic resonance imaging (fMRI).
Time frame: Baseline and end of induction phase (2 months) for participants with fatigue; single time point for control groups.
Changes in Muscle Mitochondrial Metabolism Assessed by Gene Expression Analysis
To analyze gene expression profiles related to mitochondrial metabolism in muscle fibers obtained via muscle microbiopsy. Units of measure: Relative gene expression (fold change compared to baseline or control).
Time frame: Baseline and end of induction phase (2 months) for participants with fatigue; single time point for control groups.
Change in Aerobic Capacity
Aerobic capacity will be evaluated to measure changes in functional exercise tolerance using the 6-Minute Walk Test (6MWT), which measures distance walked in meters (0-700 m typical; higher distances = better capacity). Unit of Measure: Meters.
Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).
Change in Physical Activity Levels
Physical activity levels will be assessed to determine changes in habitual activity, with scores ranging from 0 to 142, where higher scores indicate greater overall physical activity.
Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).
Change in Frailty Status
Frailty will be evaluated using the Liver Frailty Index (LFI), a continuous scale derived from a combination of grip strength, chair-stand time, and balance testing. In adult liver disease populations, median LFI values range approximately from 2.7 in individuals without liver disease to 3.6 in those with cirrhosis. Established thresholds classify LFI scores of \< 3.2 as "robust", 3.2-4.4 as "prefrail", and \> 4.4 as "frail"
Time frame: Baseline (week 0), post-intervention (week 8), and end of maintenance phase (6 months).
Feasibility and Satisfaction of a Multimodal Rehabilitation Program for the Treatment of Fatigue
Participant experience will be assessed using satisfaction questionnaires. Adherence to the intervention and loss to follow-up will be evaluated by analyzing reasons for non-compliance or withdrawal.
Time frame: From enrollment to the end of treatment at 6 months
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Clinic of Barcelona →